Neo-Optalidon (Paracetamol, Propyphenazone, Caffeine)

Paracetamol, Propyphenazone and Caffeine, the active ingredients in Neo-Optalidon, are non‑opioid analgesics presented as an oral formulation for systemic use. They relieve mild to moderate pain, headache, fever and musculoskeletal discomfort in adults.

GNH USA supplies Neo-Optalidon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Neo-Optalidon acts on pain‑related pathways and fever mechanisms to provide symptomatic relief.

Headache: reduces pain intensity and associated discomfort. Fever: lowers elevated body temperature. Musculoskeletal pain: eases aches and stiffness in muscles and joints.

Common Side Effects: - Nausea or upset stomach. - Dizziness or light‑headedness. - Insomnia or restlessness. - Increased heart rate.

Serious or Rare Side Effects: - Allergic reactions such as rash, swelling or anaphylaxis. - Hepatic injury or elevated liver enzymes. - Blood disorders including thrombocytopenia. - Severe skin reactions like Stevens‑Johnson syndrome.

Before using Neo-Optalidon, consider the following precautions: - Assess liver function: evaluate baseline hepatic status in patients with liver disease. - Avoid in known hypersensitivity: discontinue if rash or swelling occurs. - Use caution with anticoagulants: monitor for increased bleeding. - Limit use in pregnancy: consult a healthcare professional before administration. - Store at ambient temperature: keep in the original pack, protect from moisture.

Neo-Optalidon may interact with several medicines.

Major Interactions (Avoid): - Anticoagulants: heightened risk of bleeding. - MAO inhibitors: possible hypertensive crisis due to caffeine. - Alcohol: increased potential for liver toxicity.

Moderate Interactions (Monitor Closely): - Other NSAIDs: additive gastrointestinal irritation. - Diuretics: caffeine may enhance diuretic effect. - Anticonvulsants: may reduce paracetamol analgesic efficacy.